



Biofilm Formation and Control

Guest Editors:

Dr. Rita Teixeira-Santos

LEPABE – Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

Dr. Luciana C. Gomes

LEPABE – Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

Dr. Filipe J. Mergulhão

LEPABE – Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

Deadline for manuscript submissions:

31 May 2024



mdpi.com/si/137191

Message from the Guest Editors

Biofilms are structured communities of microbial cells that can form everywhere, and in general, exhibit higher resistance to antibiotics and environmental stresses than their planktonic counterparts. Because they cause serious problems in clinical, industrial, and environmental settings, a better understanding of the dynamics of biofilm formation, as well as the development of new strategies capable of inhibiting and controlling them, is needed.

Hence, this special issue targets the assessment of biofilm formation and the design of novel antibiofilm strategies to control its formation in different settings, including, but not limited to:

- Methods for biofilm monitoring
- Biofilm components quantification (proteins and EPS)
- Multispecies biofilm interactions
- Pharmacokinetic and pharmacodynamic models of biofilm control using novel antimicrobial agents
- Probiotics or probiotic-derived metabolites
- Bacteriophages and bacteriophage-derived enzymes
- Antimicrobial peptides
- Surface modification strategies to prevent biofilm formation
- Natural biofilm inhibitors
- Non-antibiotic drugs
- Combined therapies
- Novel strategies against polymicrobial biofilms

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)